Retatrutide UK: Complete Research Guide (2026)

If you've searched anything peptide-related in the last year, one name keeps coming back: retatrutide. It dominates UK search data, it dominates the research conversation, and in our own shop's sales it outsells everything else several times over. Yet most of what's written about it online is either academic paywalled literature or supplier marketing. This guide is the middle ground: what retatrutide actually is, how it works, what the clinical trials showed, how it compares to tirzepatide and semaglutide, what the legal position is in the UK, and how to verify what you're buying — all in one place, and all in plain English.

One framing note before anything else, because it matters: retatrutide is a research compound. It is not licensed as a medicine anywhere in the world, including the UK, and everything sold by research suppliers — including us — is for laboratory research use only. This article is educational material. Nothing here is medical advice, dosing instruction, or a health claim.

WHAT IS RETATRUTIDE?

Retatrutide is a synthetic peptide developed by Eli Lilly, known in the literature by its development code LY3437943. It belongs to the incretin mimetic family — the same broad class as semaglutide and tirzepatide — but it was engineered to do something none of its predecessors do: activate three receptors at once.

The compound is a 39-amino-acid peptide built on a GIP (glucose-dependent insulinotropic polypeptide) backbone, modified with a fatty-acid side chain that extends its circulating half-life to roughly six days — long enough for once-weekly administration in clinical trial protocols. It is supplied in research form as a lyophilised (freeze-dried) powder, typically in 10mg, 20mg or 40mg vials, and remains stable in that form for extended periods when stored correctly.

Its research significance is simple: retatrutide is the furthest-advanced triple agonist in existence, with Phase 3 trials now complete on topline data and a regulatory filing planned for 2027. Every major finding about combined GIP/GLP-1/glucagon receptor pharmacology in the last three years has come from this molecule.

HOW RETATRUTIDE WORKS: THE TRIPLE AGONIST MECHANISM

To understand retatrutide, it helps to see it as the third step in a sequence:

• Semaglutide activates one receptor — GLP-1 (glucagon-like peptide-1), the gut hormone signal that influences insulin secretion, appetite signalling and gastric emptying.
• Tirzepatide activates two — GIP and GLP-1. Adding the GIP pathway proved to matter: in head-to-head terms, dual agonism outperformed single agonism in every published trial comparison.
• Retatrutide activates three — GIP, GLP-1 and the glucagon receptor.

The glucagon receptor is the interesting addition. Glucagon is traditionally understood as the "raise blood sugar" hormone, but its receptor is also expressed in the liver, where activation is associated with increased energy expenditure and fat metabolism in preclinical models. Retatrutide was designed to test a specific hypothesis: does adding hepatic glucagon-receptor activity to the established GIP/GLP-1 combination produce effects beyond what dual agonists achieve?

The Phase 2 data suggested the hypothesis was worth testing — and it is the reason retatrutide, rather than any other compound, sits at the centre of current metabolic research.

THE CLINICAL TRIAL DATA

Retatrutide's human data now spans Phase 2 and Phase 3 — and as of mid-2026, the Phase 3 results are in and they're the reason this compound dominates the research conversation.

Phase 2 in obesity — Jastreboff et al., New England Journal of Medicine, 2023

The landmark study: "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial" (N Engl J Med 2023;389:514-526). 338 adults with obesity were randomised to once-weekly retatrutide at 1mg, 4mg, 8mg or 12mg, or placebo, for 48 weeks.

The headline results:

• At 24 weeks, the 12mg group had lost a mean of 17.5% of body weight
• At 48 weeks, the 12mg group had lost a mean of 24.2% of body weight — against 2.1% in the placebo group
• Weight loss had not plateaued at the 48-week endpoint, meaning the study ended before the compound's full effect was reached

That 24.2% figure broke records when published — for context, the comparator compounds' flagship trials reported 14.9% (semaglutide, STEP 1) and 20.9% (tirzepatide, SURMOUNT-1). It has since been surpassed by retatrutide's own Phase 3 data — more on both below.

Phase 2 in type 2 diabetes — Rosenstock et al., The Lancet, 2023

A parallel trial in participants with type 2 diabetes, published in The Lancet, found dose-dependent reductions in both HbA1c and body weight, with weight reductions reaching roughly 17% at the highest doses over 36 weeks.

Phase 3 — TRIUMPH-1 (topline results announced May 2026, presented at ADA June 2026)

The pivotal obesity trial randomised 2,339 adults with obesity or overweight (without diabetes) to retatrutide 4mg, 9mg or 12mg, or placebo, for 80 weeks. The results set a new record for non-surgical obesity treatment:

• The 12mg group lost a mean of 28.3% of body weight at 80 weeks (roughly 70 lbs), against 2.2% on placebo
• The 9mg group lost 25.9%; the 4mg group lost 19.0%
• 45.3% of the 12mg group lost at least 30% of their body weight, and 65.3% moved below the obesity threshold (BMI under 30) entirely
• In a pre-specified extension to 104 weeks, weight loss continued rather than plateauing: the 12mg group reached a mean reduction of 30.3%

The trial also reported improvements in knee osteoarthritis pain and obstructive sleep apnoea measures in dedicated cohorts, alongside cardiometabolic markers (triglycerides, blood pressure, waist circumference).

Phase 3 in type 2 diabetes — TRANSCEND-T2D-1 (published in The Lancet, 2026)

In adults with type 2 diabetes, retatrutide met its primary endpoint at 40 weeks: HbA1c reductions of up to 2.0 percentage points, with the 12mg group losing a mean of 16.8% of body weight — again without plateau at the endpoint.

On the regulatory pathway: Eli Lilly has indicated it plans to file for approval in early 2027. Until regulators complete their review, retatrutide remains an unlicensed research compound — which is the only form in which it legally exists.

On safety: the trials report gastrointestinal effects (nausea, vomiting, diarrhoea, constipation) as the most common adverse events, dose-dependent and consistent with the broader incretin class; in TRIUMPH-1, discontinuation due to adverse events was 11.3% at 12mg versus 4.9% on placebo. This is a summary of published data, not a safety assessment — researchers should read the primary sources.

RETATRUTIDE VS TIRZEPATIDE VS SEMAGLUTIDE

The single most useful way to see where retatrutide sits is side by side with the compounds it's compared against.

Two honest caveats about this table. First, these are different trials with different participants, durations and endpoints — not head-to-head comparisons, and the percentages shouldn't be treated as a league table of efficacy. Second, tirzepatide and semaglutide are licensed medicines; retatrutide is not yet, and regulators still have to review the Phase 3 data. What the table does show accurately is why the research community's attention has moved to the triple agonist: on the data published so far, the third receptor appears to add something real.

For the head-to-head breakdown, read our retatrutide vs tirzepatide comparison.

DOSAGE IN THE PUBLISHED TRIAL PROTOCOLS

This section reports what the published clinical literature used, for research reference only. It is a citation of trial design — not dosing guidance, not a recommendation, and not applicable to any use outside a licensed clinical trial. Research compounds are supplied for laboratory research use only.

In the Phase 2 obesity trial (Jastreboff et al., 2023), retatrutide was administered once weekly by subcutaneous injection. The protocol used dose escalation: participants started at a low initial dose (2mg weekly in the escalation arms), with the dose increased every four weeks until the target maintenance dose — 1mg, 4mg, 8mg or 12mg — was reached. Escalation existed to manage the gastrointestinal tolerability that the incretin class is known for.

The same once-weekly, escalation-first design carried into the Phase 3 TRIUMPH protocols. Researchers designing in-vitro or preclinical work with lyophilised retatrutide should treat the published literature as the reference for concentration ranges, and their own institutional protocols as the authority on handling. The full schedule breakdown is in our retatrutide dosage chart: the published trial protocols.

IS RETATRUTIDE LEGAL IN THE UK?

Yes — with precise framing, because this is the question UK buyers get wrong most often.

• Misuse of Drugs Act 1971: retatrutide is not a controlled substance. It appears on no schedule, and no licence is required to possess or purchase it.
• Psychoactive Substances Act 2016: does not apply. The Act covers substances that affect mental processes; retatrutide is not psychoactive.
• Human Medicines Regulations 2012: this is the legislation that shapes the market. Retatrutide holds no MHRA marketing authorisation, which means it cannot legally be sold, advertised or supplied as a medicine, and no supplier may make medicinal claims for it. Selling it for human use would be unlawful — which is exactly why legitimate suppliers, including us, sell it strictly as a research compound and say so on every page.

The practical summary: buying retatrutide in the UK for laboratory research purposes is lawful; buying it for human use is not something any legitimate supplier will support, and any supplier implying otherwise is breaking the law — treat that implication as a red flag, not a perk.

HOW TO READ A COA (CERTIFICATE OF ANALYSIS)

High demand attracts low-quality supply, and retatrutide currently has the highest demand of any research peptide in the UK. The COA is your verification tool — here's how to read one properly.

1. Match the batch number. The COA must name the same batch number printed on your vial. A generic "sample COA" proves nothing about what you received.

2. Check identity testing, not just purity. A proper COA shows identity confirmation via HPLC and/or mass spectrometry — proof the vial contains retatrutide at all — alongside a purity figure (research-grade retatrutide should test at 98%+ purity; ours typically tests 99%+).

3. Look for the testing laboratory's identity. Independent third-party analysis carries weight; a COA from the supplier's own unnamed "lab" does not.

4. Check the appearance note. Lyophilised retatrutide should be a clean white-to-off-white cake. Discolouration, moisture or crumbling suggests degradation or poor handling.

Every vial we ship carries a batch-specific third-party COA, and we'd encourage you to hold every other supplier to the same standard — including walking away from any that can't meet it.

"RETA PENS" AND THE COUNTERFEIT PROBLEM

If you've searched for retatrutide in the UK, you've seen them: pre-filled injection pens marketed as "reta pens", usually through social media or messaging apps, often with before-and-after imagery.

Be direct about what these are: there is no licensed retatrutide pen. Retatrutide has no marketing authorisation anywhere in the world, which means every pre-filled pen product is unregulated, unverified and unlawful to sell for human use. Nobody — not you, not the seller — knows what's in them, at what concentration, or under what conditions they were filled. The MHRA has repeatedly seized counterfeit injectable peptides of exactly this type, and the seized products have ranged from under-dosed to containing no active compound at all.

The research standard is different by design: lyophilised powder in a sealed, batch-numbered vial, backed by a third-party certificate of analysis, reconstituted under laboratory conditions. If a product is pre-filled, pre-dosed, marketed with body-transformation imagery, or sold through a channel with no registered company behind it, it fails every point of the checklist above — regardless of what the label claims.

STORING RETATRUTIDE

Lyophilised retatrutide is stable at refrigerated temperature (2-8°C), protected from light, and remains stable for extended periods frozen at -20°C. In lyophilised form it tolerates short periods at ambient temperature during shipping — domestic UK delivery means your vial spends hours in transit, not weeks. Once reconstituted with bacteriostatic water, standard laboratory practice is refrigeration at 2-8°C and use within a defined window, per your protocol. Never freeze a reconstituted solution. Our retatrutide storage and stability guide covers the detail.

This is also why UK-based supply is a genuine quality factor, not just a convenience: peptides that spend two weeks in a warm customs queue arrive degraded no matter how pure they left the lab.

SOURCING RETATRUTIDE IN THE UK

We stock retatrutide in the three sizes UK researchers actually order:

• Retatrutide 10mg — £39.99
• Retatrutide 20mg — £69.99 (the most-ordered size in our own sales data)
• Retatrutide 40mg — £104.99

Every vial ships with a batch-specific third-party COA, from a UK-registered company, with UK delivery.

One practical note from our order data: roughly half of researchers ordering retatrutide add bacteriostatic water in the same order — it's the standard diluent for multi-session reconstitution work, and ordering it with the peptide saves a second parcel. BAC water 10ml is £4.95; the full explanation of what it is and why labs reorder it is in our BAC water guide.

FREQUENTLY ASKED QUESTIONS

Is retatrutide available in the UK?

Yes, as a research compound. Retatrutide is not licensed as a medicine anywhere, so it is not available on prescription — but UK research suppliers, including us, stock lyophilised retatrutide for laboratory research use, with domestic delivery.

Is retatrutide legal to buy in the UK?

Yes, for laboratory research purposes. It is not a controlled substance under the Misuse of Drugs Act 1971 and not psychoactive under the Psychoactive Substances Act 2016. It cannot be sold as or for a medicine under the Human Medicines Regulations 2012, which is why legitimate suppliers sell it strictly as a research-use-only compound.

How much does retatrutide cost in the UK?

Research-grade retatrutide typically costs £35-£45 for 10mg, £65-£75 for 20mg and £95-£110 for 40mg from UK suppliers with third-party testing. Our current prices: £39.99, £69.99 and £104.99 respectively. Dramatically cheaper product usually means untested product.

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors (GIP and GLP-1); retatrutide adds a third (glucagon). Tirzepatide is an approved medicine; retatrutide has completed Phase 3 trials but remains unlicensed until regulators review them, so it exists only as a research compound. In the trial data published so far, retatrutide showed the larger mean weight reduction (28.3% in TRIUMPH-1 vs 20.9% in SURMOUNT-1), though these were separate trials, not a head-to-head.

Is retatrutide the same as Ozempic?

No. Ozempic is a brand of semaglutide, a single-receptor (GLP-1) agonist. Retatrutide is a different molecule — a triple agonist — made by a different company, and unlike Ozempic it is not a licensed medicine.

Does retatrutide need to be refrigerated?

Yes. Lyophilised retatrutide should be stored at 2-8°C and protected from light (it tolerates longer storage frozen at -20°C). After reconstitution, refrigerate at 2-8°C and follow your protocol's use window.

What is a "reta pen"?

An unregulated pre-filled injection pen sold through informal channels. Since no licensed retatrutide product exists anywhere, every "reta pen" is unverified and unlawful to sell for human use. The research standard is a sealed lyophilised vial with a batch-matched third-party COA.

What is retatrutide's half-life?

Approximately six days in published pharmacokinetic data, which is why the clinical trial protocols administer it once weekly.

When will retatrutide be approved?

No date is set. Phase 3 trials have reported positive topline results in 2026, and Eli Lilly has said it plans to file for approval in early 2027 — a regulatory decision would follow, and no timeline is guaranteed. Until a licence is granted it remains a research compound — and any supplier selling it as a medicine now is doing so unlawfully.

Why does retatrutide research use BAC water?

Because research vials are multi-dose and used across multiple sessions — bacteriostatic water's 0.9% benzyl alcohol keeps the solution inhospitable to bacterial growth between uses. Our BAC water guide covers this in full.

THE BOTTOM LINE

Retatrutide is the triple-receptor agonist that produced the largest weight reduction ever recorded in a Phase 3 obesity trial — 28.3% at 80 weeks in TRIUMPH-1, extending to 30.3% at 104 weeks — and it is now the most-ordered research peptide in the UK. It's legal to buy for laboratory research, unlicensed as a medicine everywhere until regulators complete their review, and surrounded by enough demand that counterfeit product is a genuine hazard. Verify the COA, check the batch number, avoid anything pre-filled or marketed for human use, and store it cold.

All compounds mentioned here are supplied strictly for scientific and laboratory research applications.